• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Smallpox - Pipeline Review, H2 2012 Product Image

Smallpox - Pipeline Review, H2 2012

  • ID: 2245049
  • September 2012
  • 84 pages
  • Global Markets Direct

Smallpox – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Smallpox - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Smallpox, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Smallpox. Smallpox - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Smallpox.
- A review of the Smallpox products under development by companies and universities/research institutes based on information derived from company and industry-specific READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Smallpox Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Smallpox 9
Smallpox Therapeutics under Development by Companies 11
Smallpox Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Smallpox Therapeutics – Products under Development by Companies 19
Smallpox Therapeutics – Products under Investigation by Universities/Institutes 20
Companies Involved in Smallpox Therapeutics Development 21
Inovio Biomedical Corporation 21
Bavarian Nordic A/S 22
Symphogen A/S 23
Nanotherapeutics, Inc. 24
Aphios Corporation 25
CEL-SCI Corporation 26
CytoGenix, Inc. 27
SIGA Technologies, Inc. 28
TapImmune Inc. 29
MacroGenics, Inc. 30
AlphaVax, Inc. 31
EpiVax, Inc. 32
Chimerix, Inc. 33
NanoBio Corporation 34
Smallpox – Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
tenofovir - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Sym-002 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
cidofovir - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Imvamune - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Imvamune - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
DNA Vaccine For Viral Infection - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CEL-1000 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
tecovirimat - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
DNA Vaccine For Smallpox - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Smallpox Vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CST-102 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Smallpox Vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
APP-0303s - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
CJ-50300 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Mult. mAbs/DARTs - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ST-246 + ACAM2000 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
SmallPox Vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
PL-801 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Smallpox Therapeutics – Drug Profile Updates 67
Smallpox Therapeutics – Discontinued Products 74
Smallpox Therapeutics - Dormant Products 75
Smallpox – Product Development Milestones 76
Featured News & Press Releases 76
Jun 18, 2012: Bavarian Nordic Receives Contract From US Government To Advance Development Of New MVA-BN Based Vaccines 76
Jun 01, 2012: PharmAthene Announces Delaware Chancery Court Issues Final Order And Judgment Upholding Favorable Ruling 76
May 22, 2012: US Government Supports Phase III Study Of Bavarian Nordic's Smallpox Vaccine 77
Apr 03, 2012: Chimerix To Present Data On CMX001 At Needham And Future Leaders Conferences 77
Mar 01, 2012: Bavarian Nordic Submits Marketing Application For IMVAMUNE To EMA 78
Oct 28, 2011: Bavarian Nordic Receives $25m Milestone Payment After Scaling Up For Industrial Production Of IMVAMUNE 78
Oct 13, 2011: PharmAthene Submits Legal Brief In Response To SIGA Technologies's Motion For Reargument 79
Jun 27, 2011: SIGA To Sell 1.7 Million Courses Of ST-246 To National Stockpile Under Modified BARDA Contract 79
Jun 27, 2011: Chimerix And BARDA Reach Agreement Ending GAO Review Of Smallpox Antiviral Contract 80
May 13, 2011: BARDA Supports Project BioShield Contract For Smallpox Drug 81
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 83
Disclaimer 83

List of Tables
Number of Products Under Development for Smallpox, H2 2012 9
Products under Development for Smallpox – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Development by Companies, H2 2012 (Contd..1) 13
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Inovio Biomedical Corporation, H2 2012 21
Bavarian Nordic A/S, H2 2012 22
Symphogen A/S, H2 2012 23
Nanotherapeutics, Inc., H2 2012 24
Aphios Corporation, H2 2012 25
CEL-SCI Corporation, H2 2012 26
CytoGenix, Inc., H2 2012 27
SIGA Technologies, Inc., H2 2012 28
TapImmune Inc., H2 2012 29
MacroGenics, Inc., H2 2012 30
AlphaVax, Inc., H2 2012 31
EpiVax, Inc., H2 2012 32
Chimerix, Inc., H2 2012 33
NanoBio Corporation, H2 2012 34
Assessment by Monotherapy Products, H2 2012 35
Assessment by Combination Products, H2 2012 36
Assessment by Stage and Route of Administration, H2 2012 38
Assessment by Stage and Molecule Type, H2 2012 40
Smallpox Therapeutics – Drug Profile Updates 67
Smallpox Therapeutics – Discontinued Products 74
Smallpox Therapeutics – Dormant Products 75

List of Figures
Number of Products under Development for Smallpox, H2 2012 9
Products under Development for Smallpox – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Discovery and Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 35
Assessment by Combination Products, H2 2012 36
Assessment by Route of Administration, H2 2012 37
Assessment by Stage and Route of Administration, H2 2012 38
Assessment by Molecule Type, H2 2012 39
Assessment by Stage and Molecule Type, H2 2012 40

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos